Jci_page_head_homepage_01 Jci_page_head_homepage_02
Boyi Liu, John E. Linley, Xiaona Du, Xuan Zhang, Lezanne Ooi, Hailin Zhang, Nikita Gamper
Published in Volume 120, Issue 4
J Clin Invest. 2010; 120(4):1240–1252 doi:10.1172/JCI41084
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 8
M channel openers and CaCC blockers attenuate BK-induced nocifensive behavior.

(A) Cl channel blockers NPPB (10 nmol/site), NFA (50 nmol/site), DIDS (50 nmol/site), or M channel opener retigabine (RTG, 5 nmol/site) or vehicles (DMSO, Veh1; NaHCO3, Veh2) were dissolved in saline and injected into the rat hind paw 5 minutes before the injection of BK (10 nmol/site) or saline in 50 μl (second injection was done into the same site). Nocifensive behavior was quantified as the time spent licking, biting, and flinching during 30 minutes. n = 7 for each group. (B) RR attenuated CAP- but not BK-induced nocifensive behavior. RR (50 nmol/site) or vehicle were preinjected 5 minutes prior to CAP or BK injection; n = 8 for each group. (C) Injection of M channel blocker XE991 (30 nmol/site) induced nocifensive behavior and attenuated BK-induced nociception. XE991 or vehicle control were injected into the plantar surface of the right hind paw either on their own or as pretreatment prior to BK injection; n = 7 for each group. *P ≤ 0.05; **P ≤ 0.01.